Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan

Table 4 Association between NAT2-imputed phenotype, CYP1A1 and CYP1A2 genotype, and prostate cancer

	Cases	Controls	P	OR (95% CI)^a
NAT2-imputed phenotype
Rapid acetylator	206	212		1.00
Intermediate acetylator	118	121	0.69	1.05 (0.83–1.32)
Slow acetylator	27	18	0.034	1.65 (1.04–2.61)
CYP1A1
AA	207	232		1.00
GA	119	105	0.12	1.20 (0.95–1.52)
GG	25	14	0.023	1.76 (1.08–2.87)
GA + GG	144	119	0.034	1.27 (1.02–1.59)
CYP1A2
CC	34	47		1.00
CA	177	171	0.045	1.43 (1.01–2.03)
AA	140	133	0.048	1.44 (1.00–2.06)
CA + AA	317	304	0.035	1.43 (1.03–2.00)

BMI body mass index, OR odds ratio, CI confidence interval
^aOR (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake

ISSN: 1347-4715